Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), an asymptomatic precursor to conditions like Metabolic Dysfunction-Associated Steatohepatitis (MASH), fibrosis, cirrhosis, and cancer, has traditionally been difficult to identify and monitor. ENDRA is developing technology to change that.
2+ billion people globally with Steatotic Liver Disease (SLD)100M+ in the U.S. alone
Liver fat > 5% is linked to Metabolic Syndrome and serious clinical risks
Learn how ENDRA is using ultrasound to help make difficult-to-diagnose diseases easier to find and treat.
WATCH THE VIDEO >Thankfully, a simple tool is on the horizon. ENDRA’s technology, TAEUS®, offers a solution for measuring liver fat, establishing a key biomarker for metabolic disease management.
“The ability to accurately quantify fat in the liver, at the point of care, with ENDRA’s TAEUS® ultrasound could be revolutionary.”
TAEUS®’ future potential goes beyond just a single application.
Obese and fibrotic patients are not excluded from TAEUS® use.
Improves screening for SLD and allows for response to GLP-1 therapies monitoring
No invasive surgical biopsy, no ionizing radiation, no risky contrast agents
Can be used at the point of patient care, providing answers more quickly and efficiently
ENDRA operates a Quality Management System which complies with the requirements of ISO 13485:2016 & EN ISO 13485:2016 for the following scope:
Certificate number: MD 697226
Effective Date: 2025-04-02
Expiry Date: 2028-04-01